- Home
- DGII vs ADPT Comparison
DGII vs ADPT Comparison
Compare DGII & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DGII
- ADPT
- Stock Information
- Founded
- DGII 1985
- ADPT 2009
- Country
- DGII United States
- ADPT United States
- Employees
- DGII N/A
- ADPT N/A
- Industry
- DGII Computer peripheral equipment
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DGII Technology
- ADPT Health Care
- Exchange
- DGII Nasdaq
- ADPT Nasdaq
- Market Cap
- DGII 1.2B
- ADPT 1.4B
- IPO Year
- DGII N/A
- ADPT 2019
- Fundamental
- Price
- DGII $33.02
- ADPT $10.33
- Analyst Decision
- DGII Hold
- ADPT Strong Buy
- Analyst Count
- DGII 4
- ADPT 7
- Target Price
- DGII $33.50
- ADPT $10.57
- AVG Volume (30 Days)
- DGII 149.5K
- ADPT 1.3M
- Earning Date
- DGII 08-06-2025
- ADPT 07-31-2025
- Dividend Yield
- DGII N/A
- ADPT N/A
- EPS Growth
- DGII 196.64
- ADPT N/A
- EPS
- DGII 1.13
- ADPT N/A
- Revenue
- DGII $418,624,000.00
- ADPT $189,527,000.00
- Revenue This Year
- DGII $1.81
- ADPT $24.46
- Revenue Next Year
- DGII $4.34
- ADPT $20.25
- P/E Ratio
- DGII $29.53
- ADPT N/A
- Revenue Growth
- DGII N/A
- ADPT 8.61
- 52 Week Low
- DGII $20.17
- ADPT $2.99
- 52 Week High
- DGII $37.07
- ADPT $10.87
- Technical
- Relative Strength Index (RSI)
- DGII 56.69
- ADPT 63.80
- Support Level
- DGII $32.87
- ADPT $9.90
- Resistance Level
- DGII $33.61
- ADPT $10.85
- Average True Range (ATR)
- DGII 0.66
- ADPT 0.48
- MACD
- DGII -0.23
- ADPT -0.01
- Stochastic Oscillator
- DGII 50.59
- ADPT 72.58
About DGII Digi International Inc.
Digi International Inc is a Minnesota corporation. The company provides business and mission-critical and Internet of Things (IoT) connectivity products and services. It has two segments: IoT Products and Services and IoT Solutions. The IoT Products and Services segment consists of distinct communications products and communication product development services. IoT Solutions segment offers wireless temperature and other environmental condition monitoring services as well as employee task management services. The company generates majority of its revenue from the IoT Products & Services segment. Geographically, the company generates majority of its revenue from its business in the United States and also has its presence in Europe, Middle East and Africa and Rest of the world.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).